DR. MICHAEL EDWIN KALAFER, M.D.
Osteopathic Medicine at Prospect Pl, San Diego, CA

License number

California G23959

Personal information

See more information about MICHAEL EDWIN KALAFER at radaris.com

Name

Address

Phone

Michael Kalafer, age 79

1330 Willow St, San Diego, CA 92106

Michael Kalafer

San Diego, CA

(619) 501-9273

Michael E Kalafer

7420 Caminito Bassano, La Jolla, CA 92037

(858) 551-0907

Michael E Kalafer, age 78

2444 Via Aprilia, Del Mar, CA 92014

Professional information

Medical Director At Sharp Coronado Hospital Sub-Acute Unit

Position:

Medical Director at Sharp Coronado Hospital Sub-Acute Unit, Medical Director at Carmel Mountain Rehab Sub-Acute Unit, Advisor at International Early Lung Cancer Action Project-Cornell University Weill Medical College, Associate Clinical Professor of Medicine at University of California, SPECIAL COURSES at School of Medicine

Location:

Greater San Diego Area

Industry:

Pharmaceuticals

Work:

Sharp Coronado Hospital Sub-Acute Unit since Jan 2010 - Medical Director Carmel Mountain Rehab Sub-Acute Unit since Jan 2010 - Medical Director International Early Lung Cancer Action Project-Cornell University Weill Medical College since Aug 2003 - Advisor University of California since Jul 1989 - Associate Clinical Professor of Medicine School of Medicine since Dec 1982 - SPECIAL COURSES Medicinova, Inc Nov 2006 - Jun 2009 - Chief Medical Officer Medicinova Nov 2006 - Jun 2009 - Chief Medical Officer Diego County Health Department Jul 2005 - Nov 2006 - Physician Volunteer Sharp Memorial and Sharp Cabrillo Hospital Feb 2001 - Aug 2003 - Principal Investigator Sharp Multidisciplinary Lung Cancer Program Jun 1998 - Aug 2003 - Medical Director Sharp Memorial Hospital Feb 1992 - Aug 2003 - Medical Director Pulmonary Services Pulmonary Center Feb 1982 - Aug 2003 - Associate Director Pulmonary Center Jan 1982 - Aug 2003 - Associate Director Sharp HealthCare 1982 - 2003 - Medical Director Transitional Hospitals Corporation Jan 1995 - Dec 1997 - Medical Director Vencor Hospital May 1996 - Apr 1997 - Medical Director Pulmonary Medicine Feb 1978 - Jan 1982 - Private practice

Education:

Recertified 1997
MEDICAL LICENSURE: State of California (G23959) 1975
State University of New York Upstate Medical University 1966 - 1970
Cornell University 1962 - 1966
Cornell University
S.U.N.Y. - Upstate Medical Center

Dr. Michael E Kalafer, San Diego CA - MD (Doctor of Medicine)

Specialties:

Critical Care Medicine, Pulmonology

Address:

1220 Rosecrans St, San Diego 92106
250 Prospect Pl, Coronado 92118

Certifications:

Critical Care Medicine, 1997, Internal Medicine, 1975, Pulmonary Disease, 1978

Awards:

Healthgrades Honor Roll

Languages:

English, Spanish

Hospitals:

1220 Rosecrans St, San Diego 92106
250 Prospect Pl, Coronado 92118
Sharp Coronado Hospital
250 Prospect Pl, Coronado 92118

Education:

Medical School
Upstate Medical University/ College of Health Professions
Graduated: 1970
Mount Sinai Hospital
Uc San Diego Med Ctr

Michael Edwin Kalafer, San Diego CA

Specialties:

Pulmonologist

Address:

1220 Rosecrans St, San Diego, CA 92106
250 Prospect Pl, Coronado, CA 92118

Education:

State University of New York, Upstate Medical University - Doctor of Medicine
UCSD Healthcare - Fellowship - Pulmonary Disease (Internal Medicine)
UCSD Healthcare - Residency - Internal Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)

Ibudilast And Immunomodulators Combination

US Patent:

2010026, Oct 14, 2010

Filed:

Apr 7, 2010

Appl. No.:

12/755939

Inventors:

Richard E. GAMMANS - Vass NC, US
Kenneth W. Locke - Carlsbad CA, US
Michael E. Kalafer - San Diego CA, US

International Classification:

A61K 31/437, A61K 38/17, A61K 31/225, A61K 31/7076, A61K 31/4704, A61K 31/137, A61K 39/395, A61K 38/02, A61P 37/06, A61P 25/00

US Classification:

4241331, 514 179, 514547, 514 46, 514312, 514653, 514300

Abstract:

The invention contemplates methods and compositions for treating multiple sclerosis including the administration of a PDE inhibitor and at least one immunomodulator comprising mitoxantrone, natalizumab, fingolimod, laquinimod, cladribine, dimethylfumarate or a mixture comprising synthetic polypeptide analogs of myelin basic protein, including alanine, glutamic acid, lysine, and tyrosine amino acid residues, in a therapeutically effective amount. A preferred PDE inhibitor includes ibudilast.